WO2020103961A3 - 一种脑部肿瘤靶向肽及其应用 - Google Patents

一种脑部肿瘤靶向肽及其应用 Download PDF

Info

Publication number
WO2020103961A3
WO2020103961A3 PCT/CN2020/072652 CN2020072652W WO2020103961A3 WO 2020103961 A3 WO2020103961 A3 WO 2020103961A3 CN 2020072652 W CN2020072652 W CN 2020072652W WO 2020103961 A3 WO2020103961 A3 WO 2020103961A3
Authority
WO
WIPO (PCT)
Prior art keywords
brain tumor
targeting peptide
application
nucleic acid
linked
Prior art date
Application number
PCT/CN2020/072652
Other languages
English (en)
French (fr)
Other versions
WO2020103961A9 (zh
WO2020103961A2 (zh
Inventor
林坚
陈龙
李成鹏
李朝刚
Original Assignee
江苏集萃分子工程研究院有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 江苏集萃分子工程研究院有限公司 filed Critical 江苏集萃分子工程研究院有限公司
Priority to US17/295,566 priority Critical patent/US20220331440A1/en
Publication of WO2020103961A2 publication Critical patent/WO2020103961A2/zh
Publication of WO2020103961A3 publication Critical patent/WO2020103961A3/zh
Publication of WO2020103961A9 publication Critical patent/WO2020103961A9/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C12N2810/405—Vectors comprising RGD peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明涉及一种脑部肿瘤的靶向肽，其编码核酸，以及包含所述编码核酸的载体、宿主细胞。所述靶向肽连接诊断标记可用于脑部肿瘤诊断，特别是脑部肿瘤成像；所述靶向肽连接治疗性药物可携带药物直达脑部肿瘤病灶实现脑部肿瘤的治疗。
PCT/CN2020/072652 2018-11-21 2020-01-17 一种脑部肿瘤靶向肽及其应用 WO2020103961A2 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/295,566 US20220331440A1 (en) 2018-11-21 2020-01-17 Brain tumor-targeting peptide and application thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201811392953.1 2018-11-21
CN201811392953.1A CN109678966B (zh) 2018-11-21 2018-11-21 一种脑部肿瘤靶向肽及其应用

Publications (3)

Publication Number Publication Date
WO2020103961A2 WO2020103961A2 (zh) 2020-05-28
WO2020103961A3 true WO2020103961A3 (zh) 2020-07-09
WO2020103961A9 WO2020103961A9 (zh) 2021-07-08

Family

ID=66184874

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/072652 WO2020103961A2 (zh) 2018-11-21 2020-01-17 一种脑部肿瘤靶向肽及其应用

Country Status (3)

Country Link
US (1) US20220331440A1 (zh)
CN (1) CN109678966B (zh)
WO (1) WO2020103961A2 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109678966B (zh) * 2018-11-21 2021-03-19 江苏集萃分子工程研究院有限公司 一种脑部肿瘤靶向肽及其应用
CN109666973B (zh) * 2018-11-21 2022-11-04 北京大学 一种穿过血脑屏障的肽库及其筛选方法
CN112048013B (zh) * 2019-06-05 2021-11-05 深圳先进技术研究院 靶向脑胶质瘤的多肽化合物及其合成方法与应用
CN113425852B (zh) * 2021-05-24 2022-06-03 北京大学 一种可穿过血迷路屏障的偶联物及其制备方法
CN113480603B (zh) * 2021-07-13 2022-03-01 四川大学 一种靶向脑胶质瘤细胞的特异性短肽、编码基因及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103083689A (zh) * 2011-11-01 2013-05-08 复旦大学 一种用于脑肿瘤诊断的跨血脑屏障靶向多模态纳米药物
CN106699845A (zh) * 2015-11-12 2017-05-24 复旦大学 stapled-RGD多肽及其在肿瘤靶向递送中的应用
CN109666973A (zh) * 2018-11-21 2019-04-23 北京大学 一种穿过血脑屏障的肽库及其筛选方法
CN109678966A (zh) * 2018-11-21 2019-04-26 江苏集萃分子工程研究院有限公司 一种脑部肿瘤靶向肽及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103083689A (zh) * 2011-11-01 2013-05-08 复旦大学 一种用于脑肿瘤诊断的跨血脑屏障靶向多模态纳米药物
CN106699845A (zh) * 2015-11-12 2017-05-24 复旦大学 stapled-RGD多肽及其在肿瘤靶向递送中的应用
CN109666973A (zh) * 2018-11-21 2019-04-23 北京大学 一种穿过血脑屏障的肽库及其筛选方法
CN109678966A (zh) * 2018-11-21 2019-04-26 江苏集萃分子工程研究院有限公司 一种脑部肿瘤靶向肽及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CUITIAN CHEN , ZIQING DUAN ,YAN YUAN , RUIXIANG LI , LIANG PANG , JIANMING LIANG , XINCHUN XU , JIANXIN WANG: "Peptide-22 and Cyclic RGD Functionalized Liposomes for Glioma Targeting Drug Delivery Overcoming BBB and BBTB", ACS APPLIED MATERIALS & INTERFACES, vol. 9, no. 7, 22 February 2017 (2017-02-22), pages 5864 - 5873, XP055389560, ISSN: 1944-8244, DOI: 10.1021/acsami.6b15831 *
GAO, HUILE: "Design and Evaluation of Brain Tumor Targeting Delivery System Based on Different Targeting Strategies", CHINESE DOCTORAL DISSERTATION FUDAN UNIVERSITY , no. 3, 15 March 2015 (2015-03-15), pages 1 - 161, XP009521843, ISSN: 1674-022X *

Also Published As

Publication number Publication date
WO2020103961A9 (zh) 2021-07-08
CN109678966B (zh) 2021-03-19
US20220331440A1 (en) 2022-10-20
WO2020103961A2 (zh) 2020-05-28
CN109678966A (zh) 2019-04-26

Similar Documents

Publication Publication Date Title
WO2020103961A3 (zh) 一种脑部肿瘤靶向肽及其应用
WO2018033254A3 (en) Rna for cancer therapy
MX2017014083A (es) Polipeptido de fusion anti-cancer.
PH12015501092A1 (en) Anti-ceacam5 antibodies and uses thereof
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
ZA202002094B (en) Trispecific proteins and methods of use
WO2016061286A3 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
WO2019033043A3 (en) ANTI-CD8 ANTIBODIES AND USES THEREOF
WO2017134302A3 (en) Targeted therapeutic agents and uses thereof
WO2017077329A3 (en) Nucleic acids, peptides and methods
WO2015031771A3 (en) Administration of kynurenine depleting enzymes for tumor therapy
WO2015024667A8 (en) Method for increasing expression of rna-encoded proteins
WO2012142529A3 (en) Clonal strains of attenuated vaccinia viruses and methods of use thereof
MY162741A (en) Improved cancer therapy based on tumor associated antigens derived from cyclin D1
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
MX2016011517A (es) Peptidos de crmp2 no narcoticos que seleccionan como diana canales de sodio para el dolor cronico.
WO2011106788A3 (en) Car peptide for homing, diagnosis, & targeted therapy for pulmonary and fibrotic disorders
WO2016210376A3 (en) Therapeutic peptides and methods of use thereof
WO2015154059A3 (en) Targeting trastuzumab-resistant her2+breast cancer with a her3-targeting nanoparticle
MX2017011794A (es) Composiciones y metodos para diagnosticos y tratamiento del cancer.
TW201613964A (en) Improved A[beta] protofibril binding antibodies
EA201790178A1 (ru) Пептиды, несущие маннозо-6-фосфат, слитые с лизосомальным ферментом
CR20220249A (es) Derivados terapéuticos de interleucina-22
EA201691053A1 (ru) Соединения к рецептору фактора роста фибробластов 3 типа (fgfr3) и способы терапии
MX2018009499A (es) Anticuerpos monoclonales especificos de egfl6 y metodos de su uso.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20727565

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20727565

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 20727565

Country of ref document: EP

Kind code of ref document: A2

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 27/01/2022)